^
    3d
    MOMENTUM-1: Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment (clinicaltrials.gov)
    P2, N=153, Recruiting, RTOG Foundation, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SSTR2 (Somatostatin Receptor 2)
    |
    Avastin (bevacizumab) • sunitinib • everolimus • hydroxyurea • Lutathera (lutetium Lu 177 dotatate)
    4d
    A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab (clinicaltrials.gov)
    P1/2, N=140, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=200 --> 140
    Enrollment closed • Enrollment change
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Lutathera (lutetium Lu 177 dotatate)
    5d
    A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. (clinicaltrials.gov)
    P1, N=65, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Jul 2027
    Enrollment closed • Trial completion date
    |
    temozolomide • Lutathera (lutetium Lu 177 dotatate)
    5d
    Predicting eligibility for outpatient 177Lu-DOTATATE-targeted radionuclide therapy in patients with neuroendocrine tumors. (PubMed, Nucl Med Commun)
    The whole-body washout rate derived from pretreatment SSTR imaging is a strong, practical predictor for outpatient eligibility following 177Lu-DOTATATE TRT. Incorporating this simple, noninvasive marker into clinical workflow could support individualized discharge planning and improve patient access under strict radiation safety regulations.
    Journal
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Lutathera (lutetium Lu 177 dotatate)
    6d
    NELMAS: Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases (clinicaltrials.gov)
    P2, N=1, Terminated, Imperial College London | N=106 --> 1 | Trial completion date: Mar 2029 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Sep 2028 --> Oct 2025; The study has closed earlier than planned due to one of the funders decision to withdraw the financial support for the study.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    Lutathera (lutetium Lu 177 dotatate)
    8d
    Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells (clinicaltrials.gov)
    P2, N=30, Recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • SYP (Synaptophysin) • CHGA (Chromogranin A)
    |
    Lutathera (lutetium Lu 177 dotatate)
    12d
    Iodine-Negative Rare Gluteal Muscle Metastasis of Papillary Thyroid Cancer: Detected by 68 Ga-DOTATATE PET/MRI and 18 F-FDG PET/CT. (PubMed, World J Nucl Med)
    The patient, who was unresponsive to RAI therapy, was being evaluated for suitability for 177 Lu-DOTATATE therapy...Muscle metastases are extremely rare for PTC. This case exemplifies the different levels of tumoral affinity shown by aggressive variants of PTC across three distinct imaging modalities: 68 Ga-DOTATATE PET/MRI, 18 F FDG PET/CT, and whole-body iodine scintigraphy.
    Journal
    |
    TG (Thyroglobulin)
    |
    Lutathera (lutetium Lu 177 dotatate)
    27d
    Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors (clinicaltrials.gov)
    P2, N=94, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | Trial completion date: Nov 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Lutathera (lutetium Lu 177 dotatate) • Triapine (3-AP)
    28d
    SALUS: Post-Authorization Long-Term Safety Study of LUTATHERA (clinicaltrials.gov)
    P=N/A, N=1014, Active, not recruiting, Advanced Accelerator Applications | Trial completion date: Jun 2028 --> Sep 2027 | Trial primary completion date: Jun 2028 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Lutathera (lutetium Lu 177 dotatate)
    1m
    Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Jun 2026 | Trial primary completion date: Oct 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    peposertib (M3814) • Lutathera (lutetium Lu 177 dotatate)
    1m
    Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study. (PubMed, J Nucl Med)
    The tumor-to-bone marrow absorbed dose ratio was in the same range for [161Tb]Tb-DOTA-LM3 as for [177Lu]Lu-DOTATOC. The administration of 1 GBq of [161Tb]Tb-DOTA-LM3 was safe for all patients, without relevant adverse events.
    Journal
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    2ms
    Challenges and Opportunities in Radioligand Therapy. (PubMed, J Nucl Med Technol)
    Although radioiodine provides the historical foundations of theranostics, the prototype RLTs include 68Ga-DOTATATE and 177Lu-DOTATATE, which target somatostatin receptor subtype 2 in neuroendocrine tumors, and 68Ga-PSMA-617 and 177Lu-PSMA-617, which target prostate cancer. RLT, weaponized in cancer management through advances in instrumentation and radiochemistry, is transforming the nuclear oncology landscape. Equitable access to these advanced tools remains a global consideration.
    Review • Journal
    |
    SSTR (Somatostatin Receptor)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Lutathera (lutetium Lu 177 dotatate)